GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » ROC (Joel Greenblatt) %

Everest Medicines (HKSE:01952) ROC (Joel Greenblatt) % : -127.27% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Everest Medicines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -127.27%.

The historical rank and industry rank for Everest Medicines's ROC (Joel Greenblatt) % or its related term are showing as below:

HKSE:01952' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8671.78   Med: -623.47   Max: -49.89
Current: -123.05

During the past 6 years, Everest Medicines's highest ROC (Joel Greenblatt) % was -49.89%. The lowest was -8671.78%. And the median was -623.47%.

HKSE:01952's ROC (Joel Greenblatt) % is ranked better than
64.61% of 1458 companies
in the Biotechnology industry
Industry Median: -321.77 vs HKSE:01952: -123.05

Everest Medicines's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 56.70% per year.


Everest Medicines ROC (Joel Greenblatt) % Historical Data

The historical data trend for Everest Medicines's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines ROC (Joel Greenblatt) % Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -652.43 -8,671.78 -594.51 -49.89 -121.11

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only -716.78 -363.83 143.54 -120.93 -127.27

Competitive Comparison of Everest Medicines's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Everest Medicines's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Everest Medicines's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Everest Medicines's ROC (Joel Greenblatt) % falls into.



Everest Medicines ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.901 + 12.018 + 67.543) - (159.363 + 0 + 6.076)
=-84.977

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(54.534 + 20.721 + 59.514) - (271.857 + 0 + 11.225)
=-148.313

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Everest Medicines for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-903.242/( ( (706.844 + max(-84.977, 0)) + (712.543 + max(-148.313, 0)) )/ 2 )
=-903.242/( ( 706.844 + 712.543 )/ 2 )
=-903.242/709.6935
=-127.27 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Everest Medicines  (HKSE:01952) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Everest Medicines ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Everest Medicines's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Everest Medicines (HKSE:01952) Business Description

Traded in Other Exchanges
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
Executives
Fu Wei 2307 Founder of a discretionary trust who can infl
Nova Aqua Limited 2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited 2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd. 2101 Beneficial owner
Ra Capital Management, L.p. 2102 Investment manager
Kolchinsky Peter 2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p. 2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc 2201 Interest of corporation controlled by you
Fu Wei 2307 Founder of a discretionary trust who can infl
Janchor Partners Limited 2102 Investment manager
C-bridge Capital Gp, Ltd. 2501 Other
Vistra Trust (singapore) Pte. Limited 2501 Other
C-bridge Capital Gp Iv, Ltd. 2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited 2101 Beneficial owner

Everest Medicines (HKSE:01952) Headlines

No Headlines